Daily Archives: November 1, 2017

Nasdaq and Bermuda Stock Exchange Sign New Market Technology Agreement

The world’s largest offshore securities market to continue long-term technology partnership with Nasdaq

NEW YORK and HAMILTON, Bermuda, Nov. 01, 2017 (GLOBE NEWSWIRE) — Nasdaq Inc. (Nasdaq:NDAQ) and the Bermuda Stock Exchange (BSX) have signed a new agreement with Nasdaq continuing to deliver its trading technology via the Nasdaq Financial Framework. The platform has been instrumental in solidifying Bermuda’s status as a premier off-shore securities market for attracting international as well as domestic capital, and allowing for asset scalability and high-order capability.

“The core technology that underpins mission critical systems of an exchange speaks volumes to the seriousness and commitment of that exchange to the support and development of its domestic capital market and international clients that it serves,” said Greg Wojciechowski, President and CEO of Bermuda Stock Exchange. “The Bermuda Stock Exchange is proud to have Nasdaq technology powering its mission critical systems.”

“In collaborating with BSX over the past several years, Nasdaq has witnessed how well-functioning and high-performing the exchange has become,” said Carlos Patino, Head of Latin America and Caribbean, Market Technology, Nasdaq. “We look forward to continuing to expand our relationship over the coming years, and delivering technology that will support the growth ambitions of BSX.”

Nasdaq’s market infrastructure technologies, including trading, real-time risk, index, clearing, CSD and market surveillance systems are operated in more than 100 marketplaces, regulators, clearinghouses and central securities depositories across the Americas, Europe, Asia, Australia, Africa, the Middle East and the Caribbean.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

About Bermuda Stock Exchange

Established in 1971 the Bermuda Stock Exchange (BSX) is now the world’s leading fully electronic offshore securities market, with a current market capitalisation (excluding mutual funds) of over $300 bn.

There are over 850 securities listed on the BSX of which over 300 are offshore funds and 211 are Insurance Linked Securities.  Bermuda has emerged as a centre of excellence for the creation, support and listing of ILS structures.

Trading occurs daily with settlement on a rolling T+2 basis. NASDAQ market technology powers the BSX’s Central Limit Order Book trading mechanism which is tightly integrated with the Exchange’s clearing, settlement and depository platforms.

The success of the BSX lies in its innovative approach to new products and markets and its ability to offer a ‘commercially sensible’ regulatory environment.  The BSX specializes in listing and trading of capital market instruments such as equities, debt issues, funds (including Hedge Fund structures), derivative warrant programmes and is rapidly becoming a leader in providing exchange services for Insurance Linked Securities, such as Catastrophe Bonds.

The BSX, recognised by the US SEC as a Designated Offshore Securities Market, is a full member and a Member of the Board of Directors of the World Federation of Exchanges (WFE) and is located in an O.E.C.D. member nation.

The BSX was granted Approved Stock Exchange status under Australia’s Foreign Investment Fund (FIF) taxation rules, Designated Investment Exchange status by the UK’s Financial Services Authority, Recognised Stock Exchange by the UK HM Revenue and Customs, Designated Stock Exchange status under Canada’s Income Tax Act.  The BSX is also a member of America’s Central Securities Depository Association. www.bsx.com

NDAQG

For Media Inquiries

Nasdaq
Ryan Wells
ryan.wells@nasdaq.com
Direct: +44 (0) 20 3753 2231
Mobile:  +44 (0) 7809 596 390

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines

  • RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines
  • A Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full review
  • RIZAPORT® (5mg and 10mg) was granted marketing authorization in Germany and Luxembourg under the European Decentralized Procedure (DCP) and a national Marketing Authorization Application (MAA) has been submitted in Spain
  • Commercialization agreements for RIZAPORT® were signed with Grupo JUSTE S.A.Q.F. for Spain and with Pharmatronic Co. for South Korea
  • RedHill and IntelGenx continue discussions with additional potential commercialization partners for RIZAPORT® in the U.S., Europe and other territories        

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform, today announced that they have resubmitted the 505(b)(2) New Drug Application (NDA) for RIZAPORT® 10mg to the U.S. Food and Drug Administration (FDA).

RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT® offers an innovative therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.

Following a first NDA submission to the FDA in March 2013, RedHill and IntelGenx received a Complete Response Letter (CRL) from the FDA. The questions raised by the FDA, which triggered the current resubmission, primarily related to third party chemistry, manufacturing and controls (CMC) and to the packaging and labeling of the product. The FDA letter raised no questions or deficiencies relating to RIZAPORT®’s safety and bio-equivalence data and did not require additional clinical trials.

If the RIZAPORT® NDA resubmission is deemed complete and permits a full review by the FDA, a Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018.

Reza Fathi, PhD, RedHill’s Senior VP Research & Development, said: “We are very pleased with the resubmission of the U.S. NDA for RIZAPORT®, which follows the marketing authorization received for RIZAPORT® in Germany and Luxembourg under the European Decentralized Procedure. Our efforts are focused on commercializing RIZAPORT® through partners in the U.S., Europe and other territories in the near future, and we are continuing the dialogue with potential partners.”

“This resubmission of the RIZAPORT® 505(b)(2) NDA is an important milestone for IntelGenx,” commented Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We look forward to continuing to work with the FDA as we seek to bring this product to market as a new therapeutic option for the benefit of patients suffering from migraines.”

RIZAPORT® was granted marketing authorization in Germany and in Luxembourg on the basis of the European Decentralized Procedure (DCP). A national Marketing Authorization Application (MAA) has been submitted for RIZAPORT® in Spain. Under the European DCP, marketing authorization approval of RIZAPORT® in additional European countries is subject to a separate procedure to obtain additional national marketing authorizations in each country. A first commercialization agreement for RIZAPORT® was signed with Grupo JUSTE S.A.Q.F. (now Exeltis Healthcare, S.L.) for Spain, and a second commercialization agreement for RIZAPORT® was signed with Pharmatronic Co. for South Korea.

About RIZAPORT® (RHB-103):
RIZAPORT® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.’s Maxalt®. RIZAPORT® 5 mg and 10 mg were approved for marketing in Germany in October 2015 and in Luxembourg in April 2017 under the European Decentralized Procedure. A New Drug Application for RIZAPORT® was resubmitted to the U.S. FDA in October 2017. RedHill entered into licensing agreements to commercialize RIZAPORT® in Spain (with with Grupo JUSTE S.A.Q.F.) and in South Korea (with Pharmatronic Co.). Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT® is based on IntelGenx’s proprietary VersaFilm technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract. The administration method of the RIZAPORT® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its pleasant flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population1 and patients suffering from dysphagia (difficulty swallowing)1.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill promotes three gastrointestinal products in the U.S.: Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions, and EnteraGam®, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill’s clinical-stage pipeline includes: (i) TALICIA (RHB-105) an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; (ii) RHB-104 an oral combination therapy for the treatment of Crohn’s disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and a planned pivotal Phase III study for nontuberculous mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) a once-daily oral pill formulation of ondansetron with successful top-line results from a Phase III study in acute gastroenteritis and gastritis and successful top-line results from a Phase II study in IBS-D; (iv) RHB-106 an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON – a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and inflammatory gastrointestinal diseases  and (vii) RIZAPORT® (RHB-103) – an oral thin-film formulation of rizatriptan for acute migraines, with a U.S. NDA resubmitted to the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP). More information about the Company is available at: www.redhillbio.com.

About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical films based on its proprietary VersaFilm technology platform.

IntelGenx’ highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’ state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

1 Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully market Donnatal® and EnteraGam®, (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xiii) the Company’s Expanded Access Program, which allows patients with life-threatening diseases potential access, subject to regulatory and other approvals, to RedHill’s investigational new drugs that have not yet received regulatory marketing approval, if a patient suffers an adverse experience using such investigative drug, potentially adversely affecting the clinical development program of that investigational product or the Company generally; (xiv) competitive companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

Company contact:
Adi Frish
Senior VP Business Development & Licensing
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
IR contact (U.S.):
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
Mnanus@troutgroup.com

Sundance Energy Australia Limited Releases Quarterly Activities Report

DENVER, Nov. 01, 2017 (GLOBE NEWSWIRE) — Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas, reported its third quarter 2017 operating results.

Sundance produced approximately 9,292 Boe/d (net) during the third quarter 2017 and has averaged 7,635 Boe/d (net) year-to-date.  Production for the quarter was impacted by Hurricane Harvey which caused shut downs at substantially all midstream and downstream facilities servicing Sundance’s production.  The hurricane reduced production by approximately 1,000 boe/d during the quarter.  Additionally, the storm delayed the Company’s end of year completions program by approximately 30 days.

Net production for the third quarter was 854,887 Boe, as compared to net production of 559,808 Boe for the same quarter in 2016, an approximate 53% increase, and net production of 627,805 for the second quarter of 2017, an approximate 36% increase. The average estimated third quarter price received per barrel was $48.19, compared to the average West Texas Intermediate (“WTI”) price of $48.16, and per Boe was $39.34.  During the fourth quarter Louisiana Light Sweet crude (“LLS”)  has traded at approximately a $5-$6 premium to WTI representing approximately a $3 increase in LLS compared to WTI from the third quarter.  Sundance’s oil is priced at LLS less applicable transportation and quality differentials.

During the quarter the Company completed 6 wells in McMullen County and has four drilled but uncompleted (“DUC”) wells in McMullen and Atascosa County that are scheduled for completion in Q4 2017.  Upon completion of the four remaining DUCs, the Company will have finished its 14 well 2017 completion program.  Six wells began production during the quarter; the three well Teal‐Hoskins pad and the three well Libersat pad with total completed lateral length of 48,279’.

The Teal-Hoskins three well pad had an average initial production rate per well of 1,735 Boe/d, at an average of 190 boe/d per 1,000 feet. The wells are currently producing 73% oil and 87% liquids. The Libersat three well pad had an average initial production rate of 1,644 boe/d, per well at an average of 237 boe/d per 1,000 feet. The wells are currently producing 51% oil and 73% liquids. These results represent some of the Company’s best wells drilled to date.

Importantly, the Teal-Hoskins B EFS 4H and the Libersat EFS 3UH, both drilled in the upper lower Eagle Ford, are outperforming the Company’s type curve. The Company believes these initial production results substantially proves up the upper lower Eagle Ford where the Company has 147 gross remaining locations.

In Dimmit County the Red Ranch EFS 32HC and the Shook EFS 11HU continue to perform materially above expectations.  The Red Ranch EFS 32HC has averaged approximately 670 boe/d for the first 170 days of production and the Shook EFS 11HU has averaged approximately 415 boe/d for the first 170 days of production.

Well Name County SEA
Working
Interest
SEA Net
Revenue
Interest
Completed
Lateral
Length
% Oil* Peak
24‐Hour
(boe/d)
30‐Day
(boe/d)
60‐Day
(boe/d)
90‐Day
(boe/d)
Teal Hoskins EFS 1H McMullen 100% 75% 9,245 90% 1,864 1,135 1,029 935
Teal Hoskins A EFS 2H McMullen 100% 75% 8,842 88% 1,645 1,209 1,083 946
Teal Hoskins B EFS 4H McMullen 100% 75% 9,366 89% 1,696 1,125 1,010 887
Libersat EFS 1H McMullen 99% 74% 7,058 86% 1,433 886 705 691
Libersat EFS 2H McMullen 99% 74% 6,631 91% 1,750 1,258 1,156 989
Libersat EFS 3UH McMullen 99% 74% 7,137 92% 1,751 1,181 1,037 882
*Based on the longest IP period

Grace Ford, COO, commented, “We are very pleased with the well results being generated from our current completion designs in both McMullen and Dimmit Counties.  In McMullen County we are seeing strong production profiles and, to date, no interference between the lower lower and upper lower Eagle Ford.  In Dimmit County the scientific data collected in 2015 and 2016 has resulted in a step change in well performance.  In particular, the Red Ranch well is performing economically in line with our McMullen assets opening up additional highly economic drilling inventory.”

Eric McCrady, CEO, commented, “Our operations team’s focus on improving well performance continues to show results and has resulted in some of our best wells to date across our acreage position.  To date, our development program is on track with our expectations in 2017 although initial production from the four drilled but uncompleted wells has been pushed back approximately 30 days due to Hurricane Harvey.  Finalization of the Vitol agreement, in addition to the recent increase in LLS pricing, has improved oil price realizations compared to WTI and provided more than adequate liquidity to execute this year’s business plan.”

Sundance plans to report third quarter 2017 financial results in mid‐November. A separate announcement will provide additional details on the release date and a conference call to review the results.

For more information, please contact:
United States
Eric McCrady, Managing Director
Tel: +1 (303) 543 5703
Australia
Mike Hannell, Chairman
Tel: +61 8 8363 0388

About Sundance Energy Australia Limited
Sundance Energy Australia Limited (“Sundance” or the “Company”) is an Australian-based, independent energy exploration company, with a wholly owned US subsidiary, Sundance Energy Inc., located in Denver, Colorado, USA. The Company is focused on the acquisition and development of large, repeatable oil and natural gas resource plays in North America. Current activities are focused in the Eagle Ford. A comprehensive overview of the Company can be found on Sundance’s website at www.sundanceenergy.net

Summary Information

The following disclaimer applies to this document and any information contained in it. The information in this release is of general background and does not purport to be complete. It should be read in conjunction with Sundance’s periodic and continuous disclosure announcements lodged with ASX Limited that are available at www.asx.com.au and Sundance’s filings with the Securities and Exchange Commission available at www.sec.gov.  

Forward Looking Statements

This release may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same.

These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the discovery and development of oil and natural gas reserves, cash flows and liquidity, business and financial strategy, budget, projections and operating results, oil and natural gas prices, amount, nature and timing of capital expenditures, including future development costs, availability and terms of capital and general economic and business conditions. Given these uncertainties, no one should place undue reliance on any forward looking statements attributable to Sundance, or any of its affiliates or persons acting on its behalf.  Although every effort has been made to ensure this release sets forth a fair and accurate view, we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Constellation Brands Prices Offering of Senior Notes

VICTOR, N.Y., Oct. 31, 2017 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE:STZ)(NYSE:STZ.B), a leading beverage alcohol company, announced today that it priced the public offering of $2.0 billion aggregate principal amount of Senior Notes, consisting of (i)  $600.0 million of 2.000% Senior Notes due 2019 (the “2019 notes”) for a public offering price of 99.860% of the principal amount of the 2019 notes; (ii)  $700.0 million of 2.250% Senior Notes due 2020 (the “2020 notes”) for a public offering price of 99.804% of the principal amount of the 2020 notes; and (iii)  $700.0 million of 2.650% Senior Notes due 2022 (the “2022 notes”) for a public offering price of 99.582% of the principal amount of the 2022 notes (collectively, the “notes”).  The notes will be senior obligations that rank equally with all of Constellation’s other senior unsecured indebtedness, and will be guaranteed by the subsidiaries of Constellation that are guarantors under Constellation’s senior credit facility.

Closing of the offering is expected to occur on November 7, 2017. Constellation intends to use the net proceeds from the offering to repay amounts outstanding under its European Term A loan facility.

Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC are acting as the joint book-running managers of the offering. The notes are being offered only by means of a prospectus, including a prospectus supplement, copies of which may be obtained by contacting Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free at (800) 294-1322 or emailing dg.prospectus_requests@baml.com, or contacting J.P. Morgan Securities LLC collect at (212) 834-4533. Alternatively, the prospectus and prospectus supplement may be obtained by visiting EDGAR on the SEC website at http://www.sec.gov.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy notes. The notes will not be sold in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful.

About Constellation Brands
Constellation Brands is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the third-largest producer and marketer of beer for the U.S. market and the world’s leading premium wine company with a leading market position in the U.S. Constellation’s wine portfolio is complemented by select premium spirits brands. Constellation’s brand portfolio includes Corona Extra, Corona Light, Modelo Especial, Modelo Negra, Pacifico, Ballast Point, Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Franciscan Estate, Ruffino, The Prisoner, SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements which are not historical facts and relate to future plans, events or performance are forward-looking statements that are based upon management’s current expectations and are subject to risks and uncertainties. Detailed information regarding risk factors with respect to the company and the offering are included in the company’s filings with the SEC, including the prospectus and prospectus supplement for the offering.

CONTACTS

Media
Mike McGrew: 773-251-4934
Amy Martin: 585-678-7141

Investor Relations
Patty Yahn-Urlaub: 585-678-7483
Bob Czudak: 585-678-7170